Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NAGE NASDAQ:ORIC NASDAQ:SCPH NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAGENiagen Bioscience$9.45-2.4%$12.04$2.53▼$14.69$762.49M2.141.12 million shs1.35 million shsORICOric Pharmaceuticals$11.15+0.8%$8.93$3.90▼$14.67$942.58M1.54784,045 shs552,486 shsSCPHscPharmaceuticals$5.38+4.9%$3.94$1.94▼$5.65$270.82M0.38379,417 shs305,600 shsZYMEZymeworks$14.32$12.56$9.03▼$17.70$997.86M1.19573,033 shs339,890 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAGENiagen Bioscience-2.38%-14.71%-29.69%+31.43%+240.54%ORICOric Pharmaceuticals+0.81%+1.55%+19.76%+115.04%+4.30%SCPHscPharmaceuticals+4.87%+22.55%+40.10%+106.92%+15.20%ZYMEZymeworks0.00%+11.18%+14.74%+15.02%+39.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNAGENiagen Bioscience1.6605 of 5 stars3.50.00.00.03.00.00.0ORICOric Pharmaceuticals4.299 of 5 stars4.51.00.04.40.03.30.6SCPHscPharmaceuticals4.4007 of 5 stars3.54.00.04.22.61.70.6ZYMEZymeworks3.0177 of 5 stars3.54.00.00.02.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNAGENiagen Bioscience 3.00Buy$13.2239.89% UpsideORICOric Pharmaceuticals 3.00Buy$18.5766.56% UpsideSCPHscPharmaceuticals 3.00Buy$14.00160.22% UpsideZYMEZymeworks 2.90Moderate Buy$21.0046.65% UpsideCurrent Analyst Ratings BreakdownLatest SCPH, ZYME, ORIC, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$13.006/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.006/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/29/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/6/2025ORICOric PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICOric PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNAGENiagen Bioscience$99.60M7.47$0.06 per share163.65$0.60 per share15.75ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ASCPHscPharmaceuticals$36.33M7.82N/AN/A$0.27 per share19.93ZYMEZymeworks$93.38M10.69N/AN/A$6.63 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNAGENiagen Bioscience$8.55M$0.1755.59∞N/A13.07%19.06%12.20%N/AORICOric Pharmaceuticals-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)Latest SCPH, ZYME, ORIC, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCPHscPharmaceuticals-$0.30N/AN/AN/A$15.41 millionN/A8/11/2025Q2 2025ORICOric Pharmaceuticals-$0.46N/AN/AN/AN/AN/A8/7/2025N/AZYMEZymeworks-$0.52N/AN/AN/A$17.18 millionN/A5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/5/2025Q1 2025ORICOric Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNAGENiagen BioscienceN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNAGENiagen BioscienceN/A3.663.12ORICOric PharmaceuticalsN/A12.0012.00SCPHscPharmaceuticals3.865.484.61ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNAGENiagen Bioscience15.41%ORICOric Pharmaceuticals95.05%SCPHscPharmaceuticals89.52%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipNAGENiagen Bioscience9.39%ORICOric Pharmaceuticals5.55%SCPHscPharmaceuticals4.78%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNAGENiagen Bioscience12078.77 million71.37 millionN/AORICOric Pharmaceuticals8085.22 million80.49 millionOptionableSCPHscPharmaceuticals3052.79 million50.27 millionOptionableZYMEZymeworks46069.68 million67.56 millionOptionableSCPH, ZYME, ORIC, and NAGE HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Receives $21.00 Average Price Target from AnalystsJuly 19, 2025 | americanbankingnews.comZymeworks (NYSE:ZYME) Trading 7% Higher - Should You Buy?July 18, 2025 | marketbeat.comZymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?July 18, 2025 | zacks.comZymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025July 17, 2025 | quiverquant.comQZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | financialpost.comFZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | financialpost.comFZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 16, 2025 | marketbeat.comZYME | Zymeworks Inc. Annual Cash Flow Statement | MarketWatchJuly 11, 2025 | marketwatch.comBispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightJuly 9, 2025 | finance.yahoo.comZymeworks (NYSE:ZYME) Given "Neutral" Rating at HC WainwrightJuly 3, 2025 | marketbeat.comZymeworks Amends Warrant Agreement with EcoR1 CapitalJune 27, 2025 | tipranks.comZYME - Zymeworks Inc Registered Shs Dividends - MorningstarJune 27, 2025 | morningstar.comMCompanies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comAll You Need to Know About Zymeworks (ZYME) Rating Upgrade to BuyJune 20, 2025 | zacks.comZymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500June 18, 2025 | kalkinemedia.comKZymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)June 12, 2025 | seekingalpha.comWall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?June 4, 2025 | zacks.comZymeworks’ zanidatamab gains approval in China for biliary tract cancerJune 2, 2025 | msn.comRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestoneMay 30, 2025 | endpts.comEChina's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract CancerMay 30, 2025 | precisionmedicineonline.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThe Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to WatchChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock Split3 Infrastructure Stocks Riding the U.S. Building BoomBy Chris Markoch | July 14, 2025View 3 Infrastructure Stocks Riding the U.S. Building BoomPepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?By Thomas Hughes | July 19, 2025View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?Vertical Aerospace Stock Trades at Discount After VX4 MilestoneBy Jeffrey Neal Johnson | July 22, 2025View Vertical Aerospace Stock Trades at Discount After VX4 MilestoneSCPH, ZYME, ORIC, and NAGE Company DescriptionsNiagen Bioscience NASDAQ:NAGE$9.45 -0.23 (-2.38%) As of 07/22/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Oric Pharmaceuticals NASDAQ:ORIC$11.15 +0.09 (+0.81%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$10.95 -0.20 (-1.79%) As of 07/22/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.scPharmaceuticals NASDAQ:SCPH$5.38 +0.25 (+4.87%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$5.34 -0.04 (-0.65%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Zymeworks NYSE:ZYME$14.32 0.00 (0.00%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$14.25 -0.07 (-0.48%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom Block Levels Up: What S&P 500 Inclusion Means for Investors Steel Dynamics Stock Steady on Long-Term Prospects Amazon Stock Rally Hits New Highs: Buy Into Earnings? A Bullish Storm Is Brewing for High-Yield Verizon’s Share Price Forget the Hype—TSMC Is the AI Stock That Actually Delivers Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.